What is NVS's health score?

NOVARTIS AG (NVS) has a TradeApes health score of 59 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is NVS's estimated fair value?

Based on our 5-year discounted cash flow model, NOVARTIS AG's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is NVS undervalued or overvalued?

Our model currently rates NVS as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

NOVARTIS AG (NVS)

Healthcare Undervalued medium mixed

$153.76

Updated: 2026-07-18

TradeApes Score

Financial Strength

65 Healthy

Operating Trend

53 Mixed

Relative Value

55 Mixed

Capital Allocation

55 Mixed

Risk Management

70 Healthy

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.